Skip to main content
Clinical Trials/NCT03262571
NCT03262571
Terminated
Phase 3

Usefulness of Lung Ultrasound in Ambulatory Management of Patients With Chronic Heart Failure

IRCCS San Raffaele1 site in 1 country244 target enrollmentDecember 2010

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Chronic Heart Failure
Sponsor
IRCCS San Raffaele
Enrollment
244
Locations
1
Primary Endpoint
Reduction of hospitalizations for acute decompensated heart failure
Status
Terminated
Last Updated
8 years ago

Overview

Brief Summary

Purpose. The aim of this study is to evaluate whether lung ultrasound, in addition to physical examination, leads to a reduction of the admission rate for acute decompensated heart failure of patients with chronic heart failure (HF) followed in the outpatients heart failure clinic.

Methods. This is a prospective randomized study. The planned sample size consists of 440 patients with chronic HF.

The inclusion criteria are: (1) male and female aged between 18 and 90 years (2) signed written informed consent (3) history of HF for at least six months, (4) left ventricular ejection fraction < 45%, (5) adequate medical therapy for HF for at least two months.

The exclusion criteria are: (1) concomitant enrollment in other clinical studies, or treatment with experimental drugs or devices within 30 days of clinical assessment, (2) inability to undergo to the planned follow-up and procedures (3) documented pulmonary infections (3) interstitial lung disease and class 4 chronic obstructive pulmonary disease according to GOLD classification.

Patients are randomized in two groups: group A, patients undergoing to lung ultrasound and physical examination; and group B, patients undergoing to physical examination only. Patients are evaluated at baseline and after three months with medical history, Quality of Life test, physical examination, blood sample for hematochemical (creatinine, electrolytes, BNP/NTpro-BNP).

The diuretic therapy is then optimized according to the presence and severity of B-lines in group A and physical examination in group B.

Only patients enrolled in group A undergo to a lung ultrasound examination to assess the extent of pulmonary congestion, through its evidence of B-lines. B-lines originate from the contrast between air-filled structures and water-thickened pulmonary interlobular septa. This leads to linear echogenic vertical artefacts that spread from the pleural layers downwards in the screen. The ultrasound examination is performed with a handheld echocardiography device. The physician carries out a scan of the pulmonary fields, from basal towards mid and apical fields, through the midaxillary line while the patient lies supine. The quantification of B-lines is performed according to their extent over the lung fields. All the information are recorded in dedicated forms.

The results are evaluated according to the following criteria. The primary end-point is a significant reduction of hospitalizations for acute decompensated HF in group A during the follow-up period. The secondary end-points are changes of NT-proBNP values, quality of life test (QLT) score and cardiac mortality.

Registry
clinicaltrials.gov
Start Date
December 2010
End Date
March 2016
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Agricola Eustachio

MD

IRCCS San Raffaele

Eligibility Criteria

Inclusion Criteria

  • (1) male and female aged between 18 and 90 years (2) signed written informed consent (3) history of HF for at least six months, (4) left ventricular ejection fraction \< 45%, (5) adequate medical therapy for HF for at least two months.

Exclusion Criteria

  • (1) concomitant enrollment in other clinical studies, or treatment with experimental drugs or devices within 30 days of clinical assessment, (2) inability to undergo to the planned follow-up and procedures (3) documented pulmonary infections (4) interstitial lung disease, class 4 chronic obstructive pulmonary disease according to GOLD guidelines (5) chronic dialysis.

Outcomes

Primary Outcomes

Reduction of hospitalizations for acute decompensated heart failure

Time Frame: 90 days

Significant reduction of hospitalizations for acute decompensated heart failure in group A during the 90-day follow-up period.

Secondary Outcomes

  • Natriuretic peptides values(90 days)
  • Quality of life test (QLT) score(90 days)
  • Cardiac mortality(90 days)

Study Sites (1)

Loading locations...

Similar Trials